TY  - GEN
AU  - Takaki,Shintaro
AU  - Kawakami,Yoshiiku
AU  - Imamura,Michio
AU  - Aikata,Hiroshi
AU  - Takahashi,Shoichi
AU  - Ishihara,Hiroto
AU  - Tsuji,Keiji
AU  - Aimitsu,Shiomi
AU  - Kawakami,Hiroiku
AU  - Nakanishi,Toshio
AU  - Kitamoto,Mikiya
AU  - Moriya,Takashi
AU  - Satoh,Kenichi
AU  - Chayama,Kazuaki
TI  - Eicosapentaenoic acid could permit maintenance of the original ribavirin dose in chronic hepatitis C virus patients during the first 12 weeks of combination therapy with pegylated interferon-alpha and ribavirin. A prospective randomized controlled trial
SN  - 1423-0100
PY  - 2008///0422
KW  - Adult
KW  - Aged
KW  - Anemia
KW  - chemically induced
KW  - Drug Therapy, Combination
KW  - Eicosapentaenoic Acid
KW  - pharmacology
KW  - Female
KW  - Hepacivirus
KW  - drug effects
KW  - Hepatitis C, Chronic
KW  - complications
KW  - Humans
KW  - Interferon alpha-2
KW  - Interferon-alpha
KW  - administration & dosage
KW  - Male
KW  - Middle Aged
KW  - Polyethylene Glycols
KW  - Prospective Studies
KW  - Recombinant Proteins
KW  - Ribavirin
N1  - Publication Type: Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1159/000114718
ER  -